Polymers Containing Multivalent Amyloid-Beta-Binding D-Peptides and Their Use

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes the development of novel synthetic polymers made from multiple D-peptides or antibody fragments, each having a strong capacity to bind to amyloid-beta oligomers—proteins implicated in Alzheimer's disease and related disorders. By forming polymers with multiple binding components, the substances exhibit significantly improved specificity and affinity for amyloid-beta aggregates compared to their individual components. These polymers can be used in medicine both for treating diseases like Alzheimer's, by neutralizing toxic oligomers and preventing their growth, and for diagnostic purposes, by acting as probes to detect amyloid-beta oligomers at early stages.

Use CasesContent extracted from patent full text and abstract with AI.

• Therapeutic agents for treating Alzheimer's disease by neutralizing or clearing toxic amyloid-beta oligomers and fibrils in patients' brains.
• Preventive medication for individuals at risk of Alzheimer's disease by inhibiting the formation of toxic oligomers.
• Medications for other amyloid-related diseases, such as Parkinson's disease, Creutzfeldt-Jakob Disease (CJD), or diabetes where amyloid aggregation is implicated.
• Diagnostic imaging probes that detect and visualize amyloid-beta oligomers and plaques in the brain for early diagnosis and disease monitoring using imaging techniques like PET or MRI.
• Research tools for quantifying and characterizing amyloid-beta oligomers in laboratory studies.

BenefitsContent extracted from patent full text and abstract with AI.

• Much higher specificity and binding affinity for toxic amyloid-beta oligomers and fibrils due to multivalency, compared to single-peptide or antibody agents.
• Potential to slow or halt progression of Alzheimer's disease by neutralizing toxic aggregates and preventing their spread.
• Ability to function both as a treatment and as a diagnostic tool (theranostics), allowing for early intervention before irreversible brain damage occurs.
• Composed primarily of D-peptides, which are resistant to degradation by bodily enzymes, thus likely improving stability and half-life inside the body.
• Reduced likelihood of immune response or side effects compared to some previous agents.
• Possible versatility for formulation as injections, tablets, vaccines, or imaging probes, increasing their usability across medical and research fields.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to novel multivalent amyloid-beta-binding polymeric substances consisting of a plurality of substances joined together which per se already have amyloid-beta-binding properties, and the use of these substances, called "polymers" hereinbelow, especially in medicine.